Edition:
United States

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Capital Market

0.42USD
12:24pm EDT
Change (% chg)

$0.01 (+2.44%)
Prev Close
$0.41
Open
$0.43
Day's High
$0.44
Day's Low
$0.42
Volume
14,825
Avg. Vol
127,308
52-wk High
$8.70
52-wk Low
$0.31

Chart for

About

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused... (more)
No analyst recommendations are available for .

Overall

Beta: 2.79
Market Cap(Mil.): €2.94
Shares Outstanding(Mil.): 7.71
Dividend: --
Yield (%): --

Financials

  CYTX.OQ Industry Sector
P/E (TTM): -- 39.51 32.69
EPS (TTM): -74.99 -- --
ROI: -78.90 14.13 12.72
ROE: -286.17 17.35 14.85

BRIEF-Cytori Therapeutics Common Stock To Begin Trading On Adjusted Basis On May 24

* CYTORI THERAPEUTIC’S COMMON STOCK TO BEGIN TRADING ON ADJUSTED BASIS ON MAY 24, FOLLOWING ONE-FOR-TEN REVERSE SPLIT Source text for Eikon: Further company coverage:

May 23 2018

BRIEF-Cytori Reports Q1 2018 Business And Financial Results

* Q1 EARNINGS PER SHARE VIEW $-0.06 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

May 10 2018

BRIEF-Cytori Provides Update On U.S. Manufacturing And EU Approval Plans For ATI-0918, Liposomal Doxorubicin

* CYTORI PROVIDES UPDATE ON U.S. MANUFACTURING AND EU APPROVAL PLANS FOR ATI-0918, LIPOSOMAL DOXORUBICIN

Apr 30 2018

Earnings vs. Estimates